| Similar Articles |
|---|
 |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?   |
Bio-IT World
August 13, 2003
Malorye Branca |
Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm. |
HHMI Bulletin
Nov 2010 |
Fusion genes that drive solid tumors are a new target for cancer therapies The success of Gleevec and related drugs has inspired researchers to step up their hunt for the molecular defects underlying other cancers. |
Wired
August 2003
Jennifer Kahn |
The End of Cancer (As we Know it) Diagnosis. Chemotherapy. Radiation. Slow painful death. No more. A new era of cancer treatment is dawning. Meet three scientists who are using the revelations of the Human Genome Project to reshape medicine. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
HHMI Bulletin
Nov 2011
Renee Twombly |
A New Take on Retinoblastoma Basic research findings upend old thoughts on this childhood tumor. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
BusinessWeek
May 12, 2011
Robert Langreth |
Big Pharma Bets on a Novel Cancer Cure Research in epigenetics is booming. The payoff could be in the billions. |
Managed Care
November 2004
Thomas Morrow |
Pharmacogenetic, Pharmacogenomic Testing Rapidly Gaining Acceptance New tests will allow better determination of which therapies will work on which patients, thus improving care and reducing outlays for failed therapies. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Bio-IT World
October 10, 2003
Kevin Davies |
Iressa's Trials and Tribulations The Iressa experience highlights the enormous stakes surrounding breakthrough therapies. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Managed Care
May 2004
Thomas Morrow |
New Agents Regulating Tyrosine Kinase Can Be Used Against Several Cancers When traditional therapies fail in cancer treatment, turning off a chemical switch may offer hope to the hopeless. |
HHMI Bulletin
Aug 2011
Sarah C.P. Williams |
The Goldilocks of Cells Too much or too little cell death can lead to disease. Scientists are learning how to find the range that's just right. |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument. |
Scientific American
March 2009
Elaine Schattner |
A Chip against Cancer: Microfluidics Scrutinizes T Cells With just a blood sample, a device could determine whether cancer is about to spread or monitor the progress of treatment |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
HHMI Bulletin
Nov 2010
Amy Maxmen |
Driving the Immune System to Attack Cancer A researcher's longtime efforts to drive T cells to attack tumors hits pay dirt. |
The Motley Fool
July 12, 2010
Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
Bio-IT World
March 17, 2004 |
The Billion-Dollar Model Company to watch � GenPath takes a novel approach to cancer research |
BusinessWeek
June 11, 2009
Kerry Capell |
Novartis: Radically Remaking Its Drug Business CEO Dan Vasella's growth mantra for Novartis is follow the science, not the financials. |
BusinessWeek
May 23, 2005
Catherine Arnst |
If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer. |
The Motley Fool
November 2, 2004
Charly Travers |
Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
Chemistry World
August 4, 2011
Sarah Houlton |
Targeting DNA Packaging to Treat Leukaemia Scientists in the US have found a new drug target that could be important in treating acute myeloid leukaemia. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Non-Small-Cell Lung Cancer: Targeting Pathways and Patients Although the most common cancer worldwide, lung cancer remains poorly treated, with the highest mortality rate. |
AskMen.com
Jacob Franek |
New Cancer Therapies As cancer research explodes, the availability of new and innovative interventions is expanding almost daily. |
Chemistry World
June 12, 2014
Andy Extance |
Pharma vies to unleash immune system power on cancer Drug firms are investing heavily in clinical trials and collaborations as they seek to capitalize on the potential of cancer therapies that enlist or enhance our immune systems' ability to fight tumors. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
June 9, 2010
Brian Orelli |
ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
Pharmaceutical Executive
February 1, 2013
William Looney |
Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice. |
Bio-IT World
June 17, 2004 |
Minority Report With Iressa, the AstraZeneca drug approved by the FDA last year, there is a small group, maybe 10 to 20 percent of lung cancer patients, who get an almost miraculous response. Mutations may explain patient responses to the drug. |
Chemistry World
September 10, 2008
Simon Hadlington |
Failed anxiety drug could treat cancer Scientists believe they have solved the mystery of how a drug originally developed for treating anxiety can kill cancer cells. |
BusinessWeek
March 8, 2004
Arlene Weintraub |
And When ImClone's Drug Doesn't Work... Physicians have greeted ImClone Systems Inc.'s (IMCL ) cancer drug, Erbitux, with a mixture of glee and grim realism. The drug dramatically shrinks colon tumors in some patients. But in others, it has little effect -- and no one knows why. |
Bio-IT World
September 11, 2003
Kevin Davies |
Chipping Away at Cancer In Vivo, In Situ Two studies probe new applications of DNA microarrays, revealing new insights into the pathogenesis and pharmacogenomics of cancer. |
Bio-IT World
February 2006 |
News Blast Hit-to-Lead... Whole Genome... Gleevec Resistance... |
Chemistry World
July 3, 2015
Andy Extance |
Pharma queues up for checkpoint inhibitor collaborations Amid fierce rivalries over the latest generation of cancer treatments, drug makers have been weaving a complex web of collaborations on combination therapies spanning much of the pharmaceutical industry. |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
The Motley Fool
June 4, 2010
Brian Orelli |
This Cancer Drug's on a Roll Novartis' Afinitor scores another win. |
Pharmaceutical Executive
November 1, 2013
Ben Comer |
2014 Pipeline Report: The Sprint to Value Across a constellation of categories, bright new drugs are moving into position. The pharma model may have changed, but companies are keeping their blockbusters. |
Scientific American
May 2009
Christine Soares |
Cancer Clues from Embryonic Development Rethinking cancer by seeing tumors as a cellular pregnancy. |
The Motley Fool
May 10, 2005
Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice? |
Bio-IT World
November 2006
Kevin Davies |
Compute for the Cure Computational comparison offers a seductive new approach to identify new drugs for disease, as well as re-purposing existing drugs. |
Pharmaceutical Executive
November 1, 2014
Josh Baxt |
2015 Pipeline Report: Burning Bright The science of drug discovery is back on script and the stars are cued up for a new generation of breakthrough therapies. |
The Motley Fool
December 8, 2010
Brian Orelli |
Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs. |
